

DT07 Rec'd PCT/PTO 0 5 JAN 2005

GIBBONS, DEL DEO, DOLAN, GRIFFINGER & VECCHIONE

A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW
ONE RIVERFRONT PLAZA
NEWARK, N.J. 07102-5486

973-596-4500
SENDER'S DIRECT DIAL

973-596-4500
973-596-0545 Fax

973-639-6397
SENDER'S DIRECT FACSIMILE

FACSIMILEFACSIMILE NUMBER 1-703-746-9195

CONTACT NUMBER _____

To: OIPECOMPANY: USPTOFROM: Tracie HibbitsDATE: Wednesday, January 05, 2005 11:31:04 AMTOTAL NUMBER OF PAGES TRANSMITTED INCLUDING THIS COVER PAGE 04**MESSAGE**

Serial Number : 10/500,485 Filed : June 29, 2004
Art Unit : 1624 Title : Novel Alkansulfonamides
Confirmation Number : 4483

*****CONFIDENTIALITY NOTE*****

Document(s) accompanying this facsimile transmission contain(s) information from the law firm of Gibbons, Del Deo, Dolan, Griffinger & Vecchione which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited, and that the documents should be returned to this firm immediately. In this regard, if you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES INDICATED ABOVE,
PLEASE CALL US AS SOON AS POSSIBLE.

This fax was transmitted directly from a networked PC.

Attorney Docket No. : 105333-51878 (Acteli 18A/E11)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bolli et al.

Serial No. : 10/500,485 Art Unit : 1624
Filed : June 29, 2004 Confirmation Number : 4483
For : NOVEL ALKANSULFONAMIDES

Office of the Initial Patent Examination's
Group Art Unit 1624
Commissioner for Patents
Alexandria, Virginia 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of an official filing receipt from the PTO in the subject application for which issuance of a newly corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data which is:
X incorrectly entered and/or ☐ omitted.
3. Complete the following applicable item A or B:
A. X The correction(s) is/are not due to any error by applicant(s) and no fee is due.
B. ☐ At least one of the above corrections is due to applicant's error and the fee therefor under 37 CFR 1.19(h) of \$25.00 should be charged to Account No.

ERROR IN	CORRECT DATA
1. <input type="checkbox"/> Applicants' Names	1.
2. <input type="checkbox"/> Applicants' Addresses	2.
3. X Title	3. NOVEL ALKANSULFONAMIDES
4. <input type="checkbox"/> Filing Date	4.
5. <input type="checkbox"/> Serial Number	5.
6. <input type="checkbox"/> Foreign/PCT Application Re:	6.
7. X Attorney Docket Number	7. 105333-51878 (Acteli 18A/E11)



William H. Epstein
Attorney for Applicant(s)

Telephone : (973) 596-4607
Facsimile : (973) 639-6397

Gibbons, Del Deo, Dolan, Griffinger & Vecchione
One Riverfront Plaza
Newark, New Jersey 07102

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being transmitted therewith I hereby certify that this correspondence is being transmitted via facsimile to (703) 746-9195 on the date shown below addressed to Commissioner for Patents, Alexandria, Virginia 22313-1450.

Signature: Tracie Lynn Hibbits Date: 1/5/05
(Print Name) Tracie Lynn Hibbits

#808650 v1
105333-51878



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FILE FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/500,485	08/29/2004	1624	2110 105333-	(Actell 18A/E11) 51878		24	1


CONFIRMATION NO. 4483

26345
GIBBONS, DEL DEO, DOLAN, GRIFFINGER & VECCHIONE
1 RIVERFRONT PLAZA
NEWARK, NJ 07102-5497

FILING RECEIPT



0C000000014834250

FILED
1/13/05

Date Mailed: 12/28/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-748-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Martin Bolli, Allschwil, SWITZERLAND;
Christoph Boss, Allschwil, SWITZERLAND;
Martine Clozel, Binningen, SWITZERLAND;
Walter Fischli, Allschwil, SWITZERLAND;
Thomas Weller, Binningen, SWITZERLAND;

Power of Attorney:

William Epstein--20008

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP02/13970 12/10/2002

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) PCT/EP02/00002 01/02/2002

Projected Publication Date: 04/07/2005

Non-Publication Request: No

Early Publication Request: No

TitleNovel alkansulfonamides ~~as endothelin antagonists~~**Preliminary Class**

544

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).